---
reference_id: "PMID:36319078"
title: New insights into CC2D2A-related Joubert syndrome.
authors:
- Harion M
- Qebibo L
- Riquet A
- Rougeot C
- Afenjar A
- Garel C
- Louha M
- Lacaze E
- Audic-Gérard F
- Barth M
- Berquin P
- Bonneau D
- Bourdain F
- Busa T
- Colin E
- Cuisset JM
- Des Portes V
- Dorison N
- Francannet C
- Héron B
- Laroche C
- Lebrun M
- Métreau J
- Odent S
- Pasquier L
- Trujillo YP
- Perrin L
- Pinson L
- Rivier F
- Sigaudy S
- Thauvin-Robinet C
- Louvier UW
- Labayle O
- Rodriguez D
- Valence S
- Burglen L
journal: J Med Genet
year: '2023'
doi: 10.1136/jmg-2022-108754
content_type: abstract_only
---

# New insights into CC2D2A-related Joubert syndrome.
**Authors:** Harion M, Qebibo L, Riquet A, Rougeot C, Afenjar A, Garel C, Louha M, Lacaze E, Audic-Gérard F, Barth M, Berquin P, Bonneau D, Bourdain F, Busa T, Colin E, Cuisset JM, Des Portes V, Dorison N, Francannet C, Héron B, Laroche C, Lebrun M, Métreau J, Odent S, Pasquier L, Trujillo YP, Perrin L, Pinson L, Rivier F, Sigaudy S, Thauvin-Robinet C, Louvier UW, Labayle O, Rodriguez D, Valence S, Burglen L
**Journal:** J Med Genet (2023)
**DOI:** [10.1136/jmg-2022-108754](https://doi.org/10.1136/jmg-2022-108754)

## Content

1. J Med Genet. 2023 Jun;60(6):578-586. doi: 10.1136/jmg-2022-108754. Epub 2022
Nov  1.

New insights into CC2D2A-related Joubert syndrome.

Harion M(1)(2)(3), Qebibo L(4)(5), Riquet A(4)(6), Rougeot C(4)(7), Afenjar 
A(4)(8), Garel C(9)(4)(10), Louha M(4)(5), Lacaze E(3)(4), Audic-Gérard F(11), 
Barth M(12), Berquin P(13), Bonneau D(12)(14)(15), Bourdain F(16), Busa T(11), 
Colin E(12), Cuisset JM(6), Des Portes V(17), Dorison N(18), Francannet 
C(19)(20), Héron B(3), Laroche C(21), Lebrun M(22), Métreau J(23), Odent 
S(24)(25), Pasquier L(24), Trujillo YP(26), Perrin L(27), Pinson L(28), Rivier 
F(29)(30), Sigaudy S(11), Thauvin-Robinet C(31)(32), Louvier UW(33), Labayle 
O(34), Rodriguez D(3)(4)(35), Valence S(#)(3)(4)(36), Burglen L(#)(4)(5)(37).

Author information:
(1)Université de Médecine, Sorbonne Université, Paris, France 
madeleine.harion@aphp.fr.
(2)INSERM UMR 1163, Paris, France.
(3)Service de neuropédiatrie, APHP, Hôpital Trousseau, Paris, France.
(4)Centre de Référence Maladies Rares "Malformations et Maladies Congénitales du 
Cervelet", Paris, Lyon, Lille, France.
(5)Département de Génétique, Hôpital Trousseau, Paris, France.
(6)Département de Neurologie Pédiatrique, Hôpital Roger Salengro, Lille, France.
(7)Département de Neurologie Pédiatrique et Centre de Référence Déficiences 
Intellectuelles, Centre Hospitalier Universitaire de Lyon, Lyon, France.
(8)Service de Génétique Clinique, Hôpital Trousseau, Paris, France.
(9)Université de Médecine, Sorbonne Université, Paris, France.
(10)Service de Radiologie Pédiatrique, Hôpital Trousseau, Paris, France.
(11)Département de Génétique, Hôpital de la Timone, Marseille, France.
(12)Department of Biochemistry and Genetics, Angers University Hospital, Angers, 
France.
(13)Service de Neurologie Pédiatrique, Hôpital Nord, Amiens, France.
(14)U771-CNRS6214, UMR INSERM, Angers, France.
(15)School of Medicine, University of Angers, Angers, France.
(16)Centre Hospitalier de la Côte Basque, Bayonne, France.
(17)Service de Neuropédiatrie, CHU de Lyon, Lyon, France.
(18)Service de Neurochirurgie Pédiatrique, Paris, France.
(19)Service de génétique clinique, Hopital Hotel Dieu, Clermont-Ferrand, France.
(20)Centre de Référence Maladies Rares "Anomalies du Développement et syndromes 
malformatifs du Sud-Est", Clermont Ferrand, France.
(21)Pediatrics-CHREC, Limoges University Hospital, Limoges, France.
(22)Service de Génétique Clinique, Chromosomique et Moléculaire, CHU Hôpital 
Nord, Saint-Etienne, France.
(23)APHP, Service de neurologie pédiatrique, Hôpital Universitaire Bicêtre, Le 
Kremlin-Bicêtre, Paris, Île-de-France, France.
(24)Service de Génétique Clinique, CLAD Ouest, CHU Rennes, Rennes, France.
(25)Equipe Genetique Humaine, UMR 6061 CNRS, Université de Rennes1, Rennes, 
France.
(26)Service de Génétique Médicale, Centre des Affections Rares en Génétique 
Ophtalmologique - CARGO, Hôpital Civil, Strasbourg, France.
(27)Service de Médecine Physique et de Réadaptation Pédiatrique, Hôpital 
Bellevue, CHU, Saint-Etienne, France.
(28)Département de Génétique Médicale, Hôpital Arnaud de Villeneuve, CHU 
Montpellier, Montpellier, France.
(29)Neuropédiatrie, CR Maladies Neuromusculaires, CHRU Montpellier, Montpellier, 
France.
(30)U1046, INSERM, Université Montpellier, Montpellier, France.
(31)Centre de Génétique, Hôpital d'Enfants CHU Dijon, Dijon, France.
(32)Centre de Référence Maladies Rares Déficiences Intellectuelles de causes 
rare, FHU TRANSLAD, Dijon, France.
(33)Service de Neurologie Pédiatrique, Montpellier, France.
(34)University of Edinburgh, Edinburgh, UK.
(35)Universite Paris Diderot, Paris, Île-de-France, France.
(36)Centre de Référence Maladies Rares "Déficience intellectuelle de cause rare 
et polyhandicap", Paris, France.
(37)Developmental Brain Disorders Laboratory, Imagine Institute, INSERM UMR 
1163, Paris, France.
(#)Contributed equally

PURPOSE: In this study, we describe the phenotype and genotype of the largest 
cohort of patients with Joubert syndrome (JS) carrying pathogenic variants on 
one of the most frequent causative genes, CC2D2A.
METHODS: We selected 53 patients with pathogenic variants on CC2D2A, compiled 
and analysed their clinical, neuroimaging and genetic information and compared 
it to previous literature.
RESULTS: Developmental delay (motor and language) was nearly constant but 
patients had normal intellectual efficiency in 74% of cases (20/27 patients) and 
68% followed mainstream schooling despite learning difficulties. Epilepsy was 
found in only 13% of cases. Only three patients had kidney cysts, only three had 
genuine retinal dystrophy and no subject had liver fibrosis or polydactyly. 
Brain MRIs showed typical signs of JS with rare additional features. 
Genotype-phenotype correlation findings demonstrate a homozygous truncating 
variant p.Arg950* linked to a more severe phenotype.
CONCLUSION: This study contradicts previous literature stating an association 
between CC2D2A-related JS and ventriculomegaly. Our study implies that 
CC2D2A-related JS is linked to positive neurodevelopmental outcome and low rate 
of other organ defects except for homozygous pathogenic variant p.Arg950*. This 
information will help modulate patient follow-up and provide families with 
accurate genetic counselling.

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and 
permissions. Published by BMJ.

DOI: 10.1136/jmg-2022-108754
PMID: 36319078 [Indexed for MEDLINE]

Conflict of interest statement: Competing interests: None declared.